News Quantified

ADAP – adaptimmune therapeutics plc - american depositary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Adaptimmune Therapeutics plc (NASDAQ: ADAP) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK [Yahoo! Finance]

-23.3%

BEAT

Form 4 Adaptimmune Therapeutics For: Feb 20 Filed by: Bertrand William C JR

Form 4 Adaptimmune Therapeutics For: Feb 20 Filed by: Brewer Joanna Elizabeth

Form 4 Adaptimmune Therapeutics For: Feb 20 Filed by: Lunger John

Form 4 Adaptimmune Therapeutics For: Feb 20 Filed by: Piccina Cintia

Form 4 Adaptimmune Therapeutics For: Feb 20 Filed by: Norry Elliot

Top News Gainers

1/13 Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications 200.0%

11/28 Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool 23.2%

11/2 Is Adaptimmune Therapeutics plc (ADAP) Is Burning These Hedge Funds [Yahoo! Finance News] 14.6%

4/29 Form 8-K Adaptimmune Therapeutics For: Apr 29 12.6%

7/3 Form 4 Adaptimmune Therapeutics For: Jul 02 Filed by: Zaks Tal Zvi 12.1%

4/1 Form 3 Adaptimmune Therapeutics For: Apr 01 Filed by: Wood Gavin 12.1%

7/22 Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center 11.6%

4/13 2 Penny Stocks That Could Make You Rich [The Motley Fool] 10.1%

6/10 Cancer Immunotherapy Markets, 2023 - ResearchAndMarkets.com 9.7%

9/9 United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4 9.7%

Top News Decliners

8/5 Form 3 Adaptimmune Therapeutics For: Aug 01 Filed by: Lunger John -19.0%

11/6 Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update -18.6%

1/14 Form 8-K Adaptimmune Therapeutics For: Jan 13 -18.4%

5/6 Form 8-K Adaptimmune Therapeutics For: May 06 -15.1%

4/27 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) had its price target lowered by analysts at Citigroup Inc from $8.00 to $5.00. They now have a "buy" rating on the stock. -15.0%

8/1 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating. -14.9%

9/11 Form EFFECT Adaptimmune Therapeutics -13.4%

4/29 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -12.3%

8/1 The T-cell Immunotherapies Market is Projected to Reach USD 26 Billion by 2030, Growing at an Annualized Rate of 41.5%, Claims Roots Analysis -11.1%

6/5 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -11.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day